Y-mAbs Therapeutics Inc. recently delivered a presentation focusing on their Radiopharmaceutical R&D update. The presentation was led by key figures in the company, including Mike Rossi, President and Chief Executive Officer, Natalie Tucker, SVP, Radiopharmaceutical Business Unit Head, and Norman LaFrance, MD, Chief Medical and Development Officer. The company is emphasizing its commitment to advancing radiopharmaceuticals with minimal off-target effects through a fully operational theranostic platform, utilizing proprietary radiohaptens for isotope modularity. The approach aims to disrupt the existing radiopharmaceutical landscape by leveraging existing infrastructure, enhancing patient safety, and increasing physician participation throughout the treatment journey. You can access the full presentation through the link below.